Ethyl 2-Bromo-1,3-Thiazole-5-Carboxylate

When the target scaffold demands regioselective C-2 functionalization prior to carboxylate-directed late-stage diversification, Ethyl 2-Bromo-1,3-Thiazole-5-Carboxylate is introduced as the heterocyclic linchpin in continuous-flow Negishi coupling sequences. Addition ratios are controlled stoichiometrically at 1.05 to 1.15 molar equivalents relative to the organozinc reagent, with excess thiazole scavenged during inline aqueous workup to maintain residual limits below 100 ppm in the crude API intermediate. Manufacturing is conducted under ICH Q7 §8.1 process validation requirements for GMP intermediate production, with batch records demonstrating control of the critical process parameter—internal temperature at the mixing tee—within a ±2 °C band to suppress proto-debromination. Production-scale runs utilize a Pfaudler glass-lined reactor with a Corning G1 SiC microreactor module for the metalation step; the configuration minimizes residence time distribution broadening that, if left uncorrected, elevates the des-bromo impurity above the 0.15% threshold specified in USP monograph residual solvent and impurity guidelines. The downstream process isolates the coupled intermediate by isopropyl acetate extraction followed by crystallization from n-heptane/ethyl acetate at a controlled cooling ramp of 0.3 °C/min, achieving a mean purity of 99.7% as determined by HPLC with UV detection at 254 nm against a qualified reference standard. The terminal products manufactured via this route are ATP-competitive inhibitors targeting mutant BRAF kinase for precision oncology applications, with the thiazole ester serving as a non-liable masking group that withstands hydrogenolysis conditions upstream and is cleaved only during the final saponification step.

When Thiazole Ester Serves as a Latent Carboxylic Acid in ProTide Prodrug Assembly

In the production of nucleotide prodrugs employing the ProTide methodology, Ethyl 2-Bromo-1,3-Thiazole-5-Carboxylate is incorporated not as a direct coupling partner but as a protected warhead that survives phosphoramidate formation intact. The carboxylate remains masked as the ethyl ester throughout the sequence, preventing premature chelation of the MgCl₂ Lewis acid catalyst during the critical phosphoramidate bond-forming step. The addition ratio is precisely 1.00 equivalent relative to the phosphorochloridate intermediate, as deviation beyond 1.02 equivalents introduces bromide ion accumulation that accelerates catalyst decomposition and reduces diastereomeric excess below the 92% specification enforced under FDA 21 CFR §211.160 laboratory controls. The manufacturing process is governed by ICH M7(R2) guidelines for mutagenic impurity control, requiring dedicated impurity fate mapping for the 2-bromothiazole motif, with purge factor calculations validated per the Teasdale approach using physiochemical data for the parent heterocycle and its ring-opened degradants. The final ester hydrolysis to liberate the carboxylic acid prodrug moiety occurs under non-aqueous conditions using LiBr in refluxing acetonitrile at 82 °C, a method selected to avoid epimerization of the stereogenic phosphorus center—a risk when aqueous alkali is applied to thiazole esters with elevated electrophilicity at C-5. Equipment specification mandates a glass-lined reactor with tantalum thermowells, as the liberated bromide ion rapidly corrodes standard 316L stainless steel at the hydrolysis temperature, with metal ion contamination above 2 µg/L measured by ICP-MS correlating with oxidative degradation of the phenol leaving group in the final product. Terminal dosage forms are orally bioavailable phosphoramidate prodrugs of nucleoside analogues targeting HCV NS5B polymerase and SARS-CoV-2 RNA-dependent RNA polymerase, where the thiazole-derived carboxylate improves passive permeability across Caco-2 monolayers in biorelevant media.

In the synthesis of aryl amide fungicides structurally related to thifluzamide and isotianil, Ethyl 2-Bromo-1,3-Thiazole-5-Carboxylate is treated with LiOH in aqueous THF at 0–5 °C to unmask the carboxylic acid, which is subsequently condensed with substituted anilines via CDI-mediated activation to generate the thiazole-5-carboxamide pharmacophore. The bromine substituent at C-2 is deliberately retained at this stage to serve as a metabolic blocking group that slows oxidative deactivation by cytochrome P450 enzymes in the target fungal species, a strategy that requires residual free bromide content in the technical-grade intermediate to be controlled below 0.5% w/w to avoid phytotoxicity in registrant crop safety studies conducted per OECD Test Guideline 208. The addition ratio of the thiazole ester to the saponification medium is maintained at 1.0 equivalent relative to LiOH monohydrate, monitored by inline pH measurement with a tolerance of ±0.2 units; overcharging base above 1.05 equivalents results in nucleophilic displacement of the 2-bromo substituent by hydroxide, generating the inactive 2-hydroxy analog and reducing the yield of the target amide to below 60% within 15 minutes of excess base contact. Industrial-scale manufacturing is performed under ISO 9001:2015 with supplementary compliance to FAO Specification 581/TC for technical concentrate identity and purity, enforced through batch certification by an OECD GLP-accredited analytical laboratory. The production line deploys a Hastelloy C-276 vessel for the saponification, as the combination of aqueous THF, LiBr byproduct, and chloride from the CDI activation step creates a mixed-halide environment that induces pitting corrosion in standard glass-lined equipment rated below pH 2. The terminal formulated products include 24% suspension concentrate and 80% water-dispersible granule presentations labeled for the control of Rhizoctonia solani in rice paddy and Sclerotinia homoeocarpa in turfgrass, with the thiazole carboxamide present as the sole active ingredient.

A Bromine-Handle Strategy for Iterative Suzuki Coupling in Anti-Trypanosomal Lead Optimization

Pharmaceutical development programs targeting kinetoplastid diseases exploit the C-2 bromine atom of Ethyl 2-Bromo-1,3-Thiazole-5-Carboxylate for sequential palladium-catalyzed cross-coupling while the C-5 ester remains orthogonally protected. The distinguishing operational feature of this application is the required selectivity between two electrophilic sites on the thiazole core: the C-2 C–Br bond, which undergoes oxidative addition to Pd(0) with a calculated bond dissociation energy of 78–82 kcal/mol, and the C-5 ester carbonyl, which must not participate in nucleophilic attack during the coupling cycle. The selective cross-coupling is achieved using Pd(PPh₃)₄ at 2.5 mol% loading with K₂CO₃ (2.0 equiv) in a dioxane/water (4:1) mixture, where the dioxane suppresses ester hydrolysis by maintaining the water activity coefficient below 0.25. The addition ratio of the bromide substrate to boronic acid is set at 1.0:1.1, with the slight excess of boronic acid compensating for protodeboronation that competes at rates exceeding 3% per hour under the reaction conditions when the arylboronic acid bears electron-donating substituents. Occupational health compliance references the EU BAT Reference Document for the Manufacture of Organic Fine Chemicals, requiring closed-system transfer of the Pd catalyst slurry and air emission monitoring for triphenylphosphine oxide at the facility boundary. Production is executed in a 500 L glass-lined reactor retrofitted with a high-efficiency condenser operating at -15 °C to minimize dioxane loss, as solvent ratio drift beyond ±2% by volume triggers ester saponification and precipitation of the free carboxylic acid as a Pd-chelating species that poisons the catalyst and stalls conversion below 35%. Purification employs simulated moving bed chromatography with a Chiralpak IA stationary phase when the downstream target includes a stereocenter introduced in the subsequent reduction; otherwise, conventional silica gel chromatography with n-heptane/ethyl acetate gradient elution suffices. The terminal product class encompasses C-2 arylated thiazole-5-carboxylates that are advanced to diamidine and bis-guanylhydrazone lead structures evaluated in murine models of Trypanosoma brucei infection, with the ester group remaining intact to facilitate studies of metabolic stability versus the corresponding free acid.

When access to a fused thiazolo[5,4-d]thiazole core is required for an electron-transport material in organic field-effect transistors, Ethyl 2-Bromo-1,3-Thiazole-5-Carboxylate is reduced with LiAlH₄ in anhydrous THF to the corresponding primary alcohol, then oxidized to the aldehyde under Swern conditions prior to condensation with dithiooxamide. Though the thiazole ester is not the direct monomer, it functions as the single-ring precursor that defines the 2,5-substitution geometry critical to the HOMO-LUMO gap of the resulting fused heterocycle. The reduction step requires the portion-wise addition of 1.05 equivalents of LiAlH₄ per equivalent of ester, as the organoaluminum intermediates formed with excess hydride reagent undergo hydride-bromide exchange at a rate that converts 8–12% of the C-2 bromine to the corresponding C-2 hydride within 30 minutes at 0 °C—a side reaction confirmed by ¹H NMR monitoring at 400 MHz with the diagnostic singlet at δ 8.85 for the 2-H thiazole. Industry compliance for electronic-grade intermediates adheres to the SEMI C27 specification for trace metal contaminants, with individual transition metal levels (Fe, Ni, Cu, Cr) each verified below 10 ppb by TXRF analysis. Production equipment includes a glass-lined reactor equipped with a side-arm addition funnel under an argon atmosphere controlled to <5 ppm O₂ and <10 ppm H₂O as measured at the reactor vent by an in-line gas analyzer; failure of the argon blanket during the LiAlH₄ addition leads to THF peroxidation and an exotherm exceeding the 60 °C alarm set point within 45 seconds. The terminal products are benzobisthiazole and thiazolothiazole semiconducting polymers used as the active layer in n-type OFET devices fabricated on flexible polyethylene naphthalate substrates, where the absence of residual ester carbonyl groups in the polymer backbone is correlated with a threshold voltage shift of less than 0.5 V under prolonged gate-bias stress testing per IEEE 1620 procedures.

Can the Ester Survive Organomagnesium Addition at an Ortho-Ester If Bromine-Magnesium Exchange Is Faster?

Continuous manufacturing of 5-acylthiazole building blocks for tubulin polymerization inhibitors subjects Ethyl 2-Bromo-1,3-Thiazole-5-Carboxylate to a kinetic selectivity challenge: the reaction of i-PrMgCl·LiCl with the substrate undergoes a Br/Mg exchange at C-2 with a rate constant approximately 6 orders of magnitude greater than nucleophilic addition to the C-5 ethyl ester, provided the internal temperature is maintained below -20 °C. Above this inflection point, the rate differential collapses, and the yield of the desired 2-magnesiated thiazole-5-carboxylate drops from quantitative conversion to <35% as the Grignard reagent consumes the ester moiety. The addition ratio of i-PrMgCl·LiCl is critically controlled at 1.00 ± 0.02 equivalents per equivalent of substrate, with the titration endpoint determined by in situ ReactIR monitoring tracking the disappearance of the C=O stretch at 1720 cm⁻¹ and the concurrent shift of the thiazole ring breathing mode from 1485 cm⁻¹ to 1460 cm⁻¹. This procedure is conducted under a quality system aligned with ISO 13485:2016 for medical device component manufacturing when the subsequent acylated intermediate is destined for antibody-drug conjugate linker payloads requiring strict control of stereochemical and chemical purity. The manufacturing flow rig comprises a glass static mixer with a 10 mL internal volume preceding a jacketed continuous stirred-tank reactor operating with a mean residence time of 4.2 minutes; visual observation of the reaction stream via a sapphire-windowed flow cell detects the onset of ester addition by a rapid color change from pale yellow to deep amber, signaling precipitation of Mg(OEt)₂ colloids. The 2-magnesiated intermediate is trapped online with an aldehyde or Weinreb amide electrophile, and the resulting tertiary alcohol or ketone product is isolated after aqueous NH₄Cl quench and short-path distillation under vacuum at 0.05 mbar. Terminal products are benzoyl-substituted thiazole-5-carboxylates and -carboxylic acids that constitute the B-ring of aryltetralin lignan-derived antimitotic agents progressing through Phase I clinical evaluation, where the C-5 ester is converted in a final step to a hydrazide for bioconjugation.

Parallel medicinal chemistry workflows employing a DNA-encoded library platform incorporate Ethyl 2-Bromo-1,3-Thiazole-5-Carboxylate as a bifunctional tag that provides both a diversity-generating bromine handle for on-DNA cross-coupling and a covalent attachment point for oligonucleotide ligation via ester-to-amide transformation. The operational constraint unique to this application is the requirement that all chemistry be performed in aqueous solvent mixtures compatible with DNA integrity: the ester must undergo quantitative hydrolysis to the carboxylic acid at pH 10 (Na₂CO₃/NaHCO₃ buffer) without degrading the phosphodiester backbone. Hydrolysis kinetics measured by LC-MS at 25 °C show a half-life of 45 minutes for the ethyl ester under these conditions, whereas the competing DNA strand scission becomes detectable by capillary electrophoresis only after 120 minutes—establishing a processing window of 60–75 minutes for complete saponification with maintained DNA integrity. The downstream amide coupling to the amine-terminated oligonucleotide uses EDC and HOAt activation in a 1:1 DMF/water mixture with 200 mM MOPS buffer. Environmental compliance is governed by the laboratory-scale exemption thresholds in REACH Annex VII, as the aggregate annual consumption of the thiazole ester across a DEL production facility typically remains below 100 g. Production is carried out on a Tecan Freedom EVO liquid handler integrated with a Biotage Isolera purification system, and the identity of each DNA-encoded compound is confirmed by qMS analysis with a mass accuracy requirement of <5 ppm. The terminal outputs are DEL libraries comprising 10⁶–10⁸ members, each containing the thiazole scaffold, which are screened in multiplexed affinity selection assays against soluble protein targets including kinases, bromodomains, and E3 ubiquitin ligases as part of early-stage hit identification campaigns.